Filing Flows › Paysign (PAYS) › Q3 2026 › vs Q3 2025
Paysign (PAYS) Q3 2026 vs Q3 2025 (year over year)
Paysign's revenue rose $9.2M (+43%) from $21.6M in Q3 2025 to $30.8M in Q3 2026. The biggest changes: Pharma industry +$8.7M (+110%); Plasma industry +$966K (+8%); Other −$462K (-57%). Gross margin 64.7% against 56.3% (+8.4 pts).
Paysign, Q3 2026: revenue $30.8M (+43% year over year), operating margin 23.8%, net earnings $6.7M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 64.7% | 56.3% | +8.4 pts |
| Operating margin | 23.8% | 7.3% | +16.4 pts |
| Net margin | 21.9% | 10.3% | +11.6 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Pharma industry | $16.6M | $7.9M | $8.7M | +110% |
| Plasma industry | $13.8M | $12.9M | $966K | +8% |
| Other | $353K | $815K | −$462K | -57% |
| Revenue | $30.8M | $21.6M | $9.2M | +43% |
| Gross profit | $19.9M | $12.2M | $7.8M | +64% |
| Cost of revenue | $10.9M | $9.4M | $1.4M | +15% |
| Other income, net | $871K | $664K | $207K | +31% |
| Operating profit | $7.3M | $1.6M | $5.7M | +363% |
| Operating expenses | $12.6M | $10.6M | $2.0M | +19% |
| Pre-tax earnings | $8.2M | $2.2M | $5.9M | +265% |
| SG&A | $10.3M | $8.4M | $1.9M | +23% |
| Other operating costs | $2.3M | $2.2M | $119K | +5% |
| Net earnings | $6.7M | $2.2M | $4.5M | +204% |
| Income tax | $1.5M | $30K | $1.4M | 48× |
Questions
How much did Paysign's revenue grow year over year in Q3 2026?
Paysign's revenue rose $9.2M (+43%) from $21.6M in Q3 2025 to $30.8M in Q3 2026.
What drove Paysign's revenue change in Q3 2026?
Pharma industry +$8.7M (+110%); Plasma industry +$966K (+8%); Other −$462K (-57%).